Clinical Trials Directory

Trials / Suspended

SuspendedNCT04125524

Terahertz Metamaterials for Tumour Marker Concentration Identification

Status
Suspended
Phase
Study type
Observational
Enrollment
90 (actual)
Sponsor
Durham University · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

The research the investigators plan to undertake involves the use of a metamaterial at terahertz frequencies. Serum samples will be tested using the metamaterial to determine if this method can be used to measure the concentration of tumour markers present in the sample. Patients who have been tested for CEA, LDH, CA-125, CA 19-9, CA 15-3, total-hCG and AFP will be used for both the positive and negative samples.

Detailed description

The research the investigators plan to undertake involves the use of a paper substrate with a gold metamaterial on top or a plastic substrate with gold metamaterial on top in physical contact with paper. The metamaterial has an absorption peak within the terahertz frequency range to be investigated (0.75 - 1.1THz). The serum samples will be soaked into the paper fibres which will shift the absorption peak within the terahertz frequency range dependent on the concentration of tumour markers present in the sample. The serum samples will be surplus from samples tested for CEA, LDH, CA-125, CA 19-9, CA 15-3, total-hCG and AFP at the Durham and Darlington NHS Fondation Trust. The samples will be anonymised with the exception of which tumour marker they were tested for and the level measured. There will be two stages to this research project the initial stage requires 15 samples per proposed marker including 15 samples (across all markers) for negative results. This will be used to identify suitable markers to consider for the second stage. Where 50 to 90 samples of each qualifying marker will be tested dependent on the number required for statistical confidence in stage two with 10 to 18 negative samples required for each qualifying marker, again dependent on the statistical requirements for each marker.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTTerahertz metamaterialsA diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.

Timeline

Start date
2021-05-17
Primary completion
2022-10-01
Completion
2025-10-01
First posted
2019-10-14
Last updated
2023-11-01

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04125524. Inclusion in this directory is not an endorsement.